KR20060072839A - Pain control and antipyretic drugs using acetaminophen and ibuprofen - Google Patents
Pain control and antipyretic drugs using acetaminophen and ibuprofen Download PDFInfo
- Publication number
- KR20060072839A KR20060072839A KR1020040111585A KR20040111585A KR20060072839A KR 20060072839 A KR20060072839 A KR 20060072839A KR 1020040111585 A KR1020040111585 A KR 1020040111585A KR 20040111585 A KR20040111585 A KR 20040111585A KR 20060072839 A KR20060072839 A KR 20060072839A
- Authority
- KR
- South Korea
- Prior art keywords
- ibuprofen
- acetaminophen
- pain
- antipyretic
- pain control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002221 antipyretic Substances 0.000 title claims abstract description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims description 26
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims description 14
- 229960001680 ibuprofen Drugs 0.000 title claims description 14
- 229960005489 paracetamol Drugs 0.000 title claims description 13
- 208000002193 Pain Diseases 0.000 title abstract description 9
- 230000000202 analgesic effect Effects 0.000 claims abstract description 5
- 230000001754 anti-pyretic effect Effects 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical group CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 229960003428 dexibuprofen Drugs 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000829 suppository Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 통증에 심하게 시달리는 환자에게 약이나 좌약을 내복하지 않고도 해열 효과와 진통효과가 뛰어난 제재를 만들어 위 점막 손상이나 소화장애 등이 있어 경구투여를 할 수 없거나 경구약으로 조절이 어려운 심한 통증이나 발열로 인한 부작용 및 고통을 줄이기 위하여 만들었다.In the present invention, a patient with severe pain suffers from antipyretic and analgesic effects without having to take medicines or suppositories. Made to reduce the side effects and pain caused by.
Description
1. 아세트 아미노펜을 이용한 주사제1. Injection with Acetaminophen
2. 이부프로펜 제제를 이용한 주사제2. Injections Using Ibuprofen Preparation
3. 아세트아미노펜50％와 이부프로펜50％를 이용한 주사제3. Injections using 50% acetaminophen and 50% ibuprofen
급만성통증과 급성열로 야기되는 고통과 합병증을 줄이고 염증을 치료하는 안전한 치료약제로써 아세트아미노펜과 이부프로펜이 있는데 이 제제들은 경구용과 좌약이 있지만 주사제는 없었다.Acetaminophen and ibuprofen are safe treatments to reduce the pain and complications caused by acute pain and acute fever, and to treat inflammation.
통증 및 발열을 조절하는 약물로써 사용되어지고 있는 약제인 다른 비스테로이드성 진통소염제는 부작용과 위장관 합병증으로 사용이 제한되어 사용되어 왔다. 이에 효과도 빠르고 소아열을 조절하는 안전한 성분의 약으로써 아세트아미노펜과 이부프로펜 주사제를 생각하게 되었다.Other nonsteroidal analgesic drugs, which are being used as drugs to control pain and fever, have been used with limited side effects and gastrointestinal complications. As a result, acetaminophen and ibuprofen injections are considered as safe and fast-acting drugs.
이 제제를 이용하여 주사제를 만들어 투여함으로써 복용시 나타날 수 있는 위장관 합병증 및 쉽게 통증 및 발열을 조절할 수 있도록 하였다.Injections were made using this formulation to help control gastrointestinal complications and pain and fever that may occur when taken.
본 제제는 심한통증이 있는 환자 위장장애와 흡수장애가 있는 환자에게 적용이 가능한 장점이 있다.This formulation has the advantage of being applicable to patients with severe pain and gastrointestinal disorders and malabsorption.
먼저 아세트아미노펜 단일제제로 만들어. 진통효과 및 해열효과를 분석해 보아야하고, 이부프로펜 단일제제 및, 이부프로펜의 활동성 부위인 s-ibuprofen 제제(덱시부프로펜)를 이용한 주사제로 진통소염효과를 분석해 보아야 한다First, make it into acetaminophen. Analgesic and antipyretic effects should be analyzed, and analgesic anti-inflammatory effects should be analyzed with ibuprofen monotherapy and s-ibuprofen preparation (dexibuprofen), the active site of ibuprofen.
그리고 아세트아미노펜과 이부프로펜 제의 합성제제를 개발하여 아세트아미노펜과 이부프로펜을 이하 앞을 아세트 아미노펜％ 이부프로펜％으로 표기In addition, a synthetic preparation of acetaminophen and ibuprofen was developed, and acetaminophen and ibuprofen were referred to as acetaminophen% ibuprofen% in the following.
(10％+90％) (20％+80％) (30％+70％) (40％+60％) (50％+50％) (60％+40％) (70％+30％) (80％+20％) (90％+10％) (55％+45％)(10% + 90%) (20% + 80%) (30% + 70%) (40% + 60%) (50% + 50%) (60% + 40%) (70% + 30%) ( 80% + 20%) (90% + 10%) (55% + 45%)
최대효과를 낼수 있는 최적의 접합율을 연구하여 앰플이나 바이알 형태로 만든다.The optimum bonding ratio for maximum effect is studied and the ampoules or vials are formed.
해열효과와 진통효과가 있는 약제인 아세트아미노펜과 이부프로펜을 사용하여 주사제를 만들어 해열 및 진통효과를 얻을 수 있는 수 있는 제제를 만든다.Acetaminophen and ibuprofen, which are drugs that have antipyretic and analgesic effects, are used to make injections to produce antipyretic and analgesic drugs.
아세트 아미노펜의 용량은 30-40mg/kg/일 이고 하루 최대허용 용량이 4g 이므로 1바이알(앰플)당 용량은 800-1200mg 정도 되면 적당하다고 생각되고The dose of acetaminophen is 30-40mg / kg / day and the maximum allowable dose per day is 4g, so the dose per vial (800-1200mg) is considered appropriate.
이부프로펜 역시 하루용량이 30-40mg/kg 이고 하루 최대량이 3.2g 이므로 1바이알(앰플)의 용량은 500-1000mg 이면 적정용량으로 생각된다.Ibuprofen also has a daily dose of 30-40mg / kg and a maximum daily dose of 3.2g, so a dose of 1 vial (500-1000mg) is considered appropriate.
약물을 위장관으로 투여하는 방법인 복용하는 것은 구토나 설사를하는 경우나 수술환자 등에서는 사용하기 어려워 치료행위를하기가 힘들다. Taking drugs, which are administered to the gastrointestinal tract, is difficult to use in cases such as vomiting or diarrhea or in surgical patients, making treatment difficult.
심한 열이 있는 소아나 유아인 경우 해열을 하지 않으면 열성 경련등의 심한 문제를 유발시킬수 있으므로 근육주사나 정맥주사를 통하여 빠르게 유효 혈중농도에 도달하게 함으로써, 빠른 효과와 통증에서 해방될수 있도록 도움을 줄수 있다는데 큰 메리트가 있다고 본다.Infants or infants with severe fever may cause severe problems such as febrile seizures if they are not fevered, so they can help to quickly release effective blood levels through intramuscular or intravenous injections, helping them to be free from pain and pain. I think there is a big merit.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040111585A KR20060072839A (en) | 2004-12-23 | 2004-12-23 | Pain control and antipyretic drugs using acetaminophen and ibuprofen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040111585A KR20060072839A (en) | 2004-12-23 | 2004-12-23 | Pain control and antipyretic drugs using acetaminophen and ibuprofen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060072839A true KR20060072839A (en) | 2006-06-28 |
Family
ID=37165978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020040111585A Ceased KR20060072839A (en) | 2004-12-23 | 2004-12-23 | Pain control and antipyretic drugs using acetaminophen and ibuprofen |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20060072839A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012060719A1 (en) * | 2010-11-04 | 2012-05-10 | Aft Pharmaceuticals Limited | A combination composition |
| US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
-
2004
- 2004-12-23 KR KR1020040111585A patent/KR20060072839A/en not_active Ceased
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012060719A1 (en) * | 2010-11-04 | 2012-05-10 | Aft Pharmaceuticals Limited | A combination composition |
| CN103298464A (en) * | 2010-11-04 | 2013-09-11 | 阿福特药物有限公司 | compound composition |
| JP2013541583A (en) * | 2010-11-04 | 2013-11-14 | エイエフティ ファーマスーティカルズ リミテッド | Combination composition |
| JP2017132791A (en) * | 2010-11-04 | 2017-08-03 | エイエフティ ファーマスーティカルズ リミテッドＡｆｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ | Combination composition |
| US11446266B2 (en) | 2010-11-04 | 2022-09-20 | Aft Pharmaceuticals Limited | Combination composition |
| US11896567B2 (en) | 2010-11-04 | 2024-02-13 | Aft Pharmaceuticals Limited | Combination composition |
| US12220392B2 (en) | 2010-11-04 | 2025-02-11 | Aft Pharmaceuticals Limited | Combination composition |
| US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| US11534407B2 (en) | 2019-02-27 | 2022-12-27 | Aft Pharmaceuticals Limited | Pharmaceutical compostion containing acetominophen and ibuprofen |
| US11872317B2 (en) | 2019-02-27 | 2024-01-16 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetominophen and ibuprofen |
| US12194151B2 (en) | 2019-02-27 | 2025-01-14 | Aft Pharmaceuticals Limited | Pharmaceutical compostion containing acetominophen and ibuprofen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| White | The changing role of non-opioid analgesic techniques in the management of postoperative pain | |
| BRPI0708640A8 (en) | pharmaceutical composition, and methods for treating a migraine headache patient, treating a pain patient, and treating a migraine patient | |
| ES2527344T3 (en) | Flurbiprofen and muscle relaxant combinations | |
| Adil et al. | Nicolau's syndrome: A rare but preventable iatrogenic disease | |
| Sivrikaya | Multimodal analgesia for postoperative pain management | |
| RU2009118962A (en) | APPLICATION OF IL-1 ANTAGONISTS FOR TREATMENT OF GHIT AND PSEUDOGRAPHY | |
| Park et al. | Preoperative pregabalin prolongs duration of spinal anesthesia and reduces early postoperative pain: A double-blind, randomized clinical CONSORT study | |
| US20190374491A1 (en) | Topical preparation for pain relief | |
| Bourgeois et al. | Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis | |
| BRPI0416882A (en) | compound, pharmaceutical composition, method of treating a disorder, and use of a compound | |
| KR20060072839A (en) | Pain control and antipyretic drugs using acetaminophen and ibuprofen | |
| EA200501223A1 (en) | THERAPEUTIC SYSTEM CONTAINING AMOXICILNINE AND KLA-ACID | |
| EA200500941A1 (en) | MEANS FOR TREATING JOINT DISEASES | |
| KR20220015407A (en) | Combination administration of diazepam and diclofenac for the treatment of pain | |
| Lo et al. | When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis? | |
| US9687518B2 (en) | Medicament for treating muscle and skeletal diseases | |
| BR0112830A (en) | Medicinal product especially intended to combat sexual dysfunction | |
| Levy et al. | Perioperative pain and swelling control in anterior cruciate ligament reconstruction | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| Kuzmin | Postoperative analgesia with nephopam hydrochloride in plastic surgery | |
| Huijbers et al. | Propofol extravasation in a breast cancer patient | |
| CN1175886C (en) | Externally applied analgesic liquid medicine and preparation method thereof | |
| JPH0251405B2 (en) | ||
| RU2002129356A (en) | COMBINATION OF MEDICINES FOR TREATMENT OF HEADACHE CONTAINING A NON-STEROID ANTI-INFLAMMATORY MEDICINE | |
| EA201000810A1 (en) | PHARMACEUTICAL COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20041223 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060616 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20061012 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060616 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |